Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent iransfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.

The present invention relates to methods of treating multiple myeloma using an approved drug product comprising daratumumab and hyaluronidase in combination with pomalidomide and dexamethasone. Also described are methods for improving progression-free survival in multiple myeloma patients and methods of selling or offering for sale a drug product comprising daratumumab and hyaluronidase.

The invention belongs to the field of cosmetic biotechnology, and specifically relates to an Enterobacter that degrades hyaluronic acid and a cultivation method and application thereof. The Enterobacter sp. CGJ001 of the present invention was deposited in the China General Microbiological Culture Collection Center on Oct. 10, 2019, and the preservation number is CGMCC NO. 18661. The Enterobacter strain can efficiently produce hyaluronidase, and can be used in the process of preparing low molecular hyaluronic acid and oligomeric hyaluronic acid from high molecular hyaluronic acid. The enzyme has high specificity towards hyaluronic acid, excellent thermal stability and pH stability, and is suitable for large-scale industrial application. Thus, it can replace the traditional hyaluronidase extracted from expensive animal tissues. There should be broad application prospects in the fields of medicine and cosmetics.

Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.

The present disclosure generally relates to methods and compositions comprising a protein having hyaluronidase activity to diagnose the etiology of, minimize, and treat peri-orbital hollowness with or without associated thyroid disease and to treat tear trough deformity.

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab′ antibody fragment, called “FR104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.

The present disclosure provides a method of treating cellulite in a subject in need thereof by administering a composition that comprises a protein having hyaluronidase activity to a region of skin having cellulite on the subject. Also provided are methods of reducing the appearance of cellulite in a subject in need thereof comprising administering a composition that comprises a protein having hyaluronidase activity to a region of skin having cellulite on the subject, wherein the administration results in a reduction in a grade of severity of the cellulite.

The invention discloses a recombinant Corynebacterium glutamicum for efficient synthesis of highly pure hyaluronic acid and oligosaccharides thereof, belonging to the technical field of bioengineering. The recombinant Corynebacterium glutamicum constructed in the present invention can produce hyaluronic acid with a yield up to 40g/L, and a crude product purity of 95%. Addition of exogenous hyaluronic acid hydrolase and optimization of the fermentation conditions results in hyaluronic acid oligosaccharides with specific molecular weight, and can further improve the yield of hyaluronic acid to 72 g/L. The invention lays a solid foundation for the efficient synthesis of highly pure hyaluronic acid by microorganisms, and the constructed recombinant Corynebacterium glutamicum is suitable for industrial production and application.